Both the firms have signed an agreement to further develop and commercialize Adaptive’s NGS-based clonoSEQ assay to evaluate minimal residual disease (MRD) in patients with ALL.

The partnership will develop dataset for MRD as a validated measure of patient outcomes in ALL.

MRD pertains to cancer cells, which remain in the body of a person with lymphoid cancer after treatment.

Adaptive’s clonoSEQ assay helps physicians to use next-generation sequencing-based MRD detection to provide clinical decision making for patients with lymphoid malignancies.

The assay will enable to detect and quantify DNA sequences determined in malignant cells.het can be tracked across treatment.

In addition, the assay enables physicians to visualize response to treatment over time to enhance patient management.

Adaptive is seeking marketing approval from the US Food and Drug Administration (FDA) for the assay.

Adaptive Biotechnologies president, CEO and co-founder Chad Robins said: “Adaptive is fully committed to collaborating with Amgen to bring a robust, validated MRD measure to ALL patients who need better management and monitoring of their disease.

“We are excited to demonstrate through this collaboration that Adaptive’s highly accurate and sensitive clonoSEQ Assay can be used to give patients and clinicians a more reliable and validated resource to improve monitoring and management of ALL.”

Image: Amgen headquarters in Thousand Oaks, California. Photo: courtesy of Coolcaesar.